Zionsville, IN, United States of America

Danix Li


Average Co-Inventor Count = 6.5

ph-index = 1

Forward Citations = 2(Granted Patents)


Location History:

  • San Francisco, CA (US) (2011)
  • Zionsville, IN (US) (2012)

Company Filing History:


Years Active: 2011-2012

Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Danix Li

Introduction

Danix Li is a notable inventor based in Zionsville, IN (US). He has made significant contributions to the field of biotechnology, particularly in the study of the p53 pathway, which is crucial for regulating cell growth and preventing cancer.

Latest Patents

Danix Li holds 2 patents that focus on the modulation of the p53 pathway. His latest patents include "MAP3Ks as modifiers of the p53 pathway and methods of use," which identifies human MAP3K genes as therapeutic targets for disorders associated with defective p53 function. This patent provides methods for identifying modulators of p53 by screening for agents that affect the activity of MAP3K. Another significant patent is "HPRP4s modifiers of the p53 pathway and methods of use," which identifies human hPRP4 genes as modulators of the p53 pathway, also serving as therapeutic targets for related disorders. This patent outlines methods for identifying modulators of p53 through screening for agents that modulate the activity of hPRP4.

Career Highlights

Danix Li is currently employed at Exelixis, Inc., where he continues to advance research in the field of cancer therapeutics. His work has contributed to a deeper understanding of the mechanisms that underlie p53 function and its implications for cancer treatment.

Collaborations

Some of his notable coworkers include Lori Friedman and Gregory D Plowman, who collaborate with him on various research projects aimed at enhancing therapeutic strategies targeting the p53 pathway.

Conclusion

Danix Li's innovative work in the modulation of the p53 pathway highlights his significant contributions to biotechnology and cancer research. His patents reflect a commitment to advancing therapeutic options for disorders linked to p53 dysfunction.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…